Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) and Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.
Volatility and Risk
Allarity Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500.
Insider and Institutional Ownership
11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 0.2% of Allarity Therapeutics shares are owned by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings for Allarity Therapeutics and Actinium Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Allarity Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
| Actinium Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
Allarity Therapeutics currently has a consensus target price of $10.25, suggesting a potential upside of 1,045.25%. Actinium Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 342.48%. Given Allarity Therapeutics’ higher possible upside, research analysts plainly believe Allarity Therapeutics is more favorable than Actinium Pharmaceuticals.
Profitability
This table compares Allarity Therapeutics and Actinium Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Allarity Therapeutics | N/A | -152.77% | -46.50% |
| Actinium Pharmaceuticals | N/A | -100.85% | -47.89% |
Valuation & Earnings
This table compares Allarity Therapeutics and Actinium Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Allarity Therapeutics | $320,000.00 | 44.50 | -$11.23 million | ($0.78) | -1.15 |
| Actinium Pharmaceuticals | $35.09 million | 1.01 | -$48.82 million | $0.36 | 3.14 |
Allarity Therapeutics has higher earnings, but lower revenue than Actinium Pharmaceuticals. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Actinium Pharmaceuticals beats Allarity Therapeutics on 7 of the 12 factors compared between the two stocks.
About Allarity Therapeutics
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
Receive News & Ratings for Allarity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allarity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
